- Investing.com
Metrics to compare | GRI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGRIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −2.0x | −0.3x | |
PEG Ratio | 0.00 | −0.03 | 0.00 | |
Price/Book | 0.2x | 2.4x | 2.6x | |
Price / LTM Sales | - | 89.2x | 2.9x | |
Upside (Analyst Target) | - | 356.8% | 56.7% | |
Fair Value Upside | Unlock | 18.8% | 10.2% | Unlock |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.